These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6705442)

  • 1. Mechanism by which hydralazine increases propranolol bioavailability.
    Schneck DW; Vary JE
    Clin Pharmacol Ther; 1984 Apr; 35(4):447-53. PubMed ID: 6705442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.
    Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1982; 21(4):315-23. PubMed ID: 7056277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs.
    Heinzow BG; Somogyi A; McLean AJ
    Arch Int Pharmacodyn Ther; 1987 Mar; 286(1):5-14. PubMed ID: 3592861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between oral hydralazine and propranolol. II. Assessment of altered splanchnic blood flow as the determinant of altered presystemic extraction.
    Corbett H; Cahill CM; Heinzow B; Harrison PM; Byrne AJ; McLean AJ
    J Pharmacol Exp Ther; 1986 Nov; 239(2):517-21. PubMed ID: 3772806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on hydralazine. III. Bioavailability of hydralazine in man.
    Talseth T
    Eur J Clin Pharmacol; 1976; 10(6):395-401. PubMed ID: 1001354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of vitamin C on the absorption and first pass metabolism of propranolol.
    Gonzalez JP; Valdivieso A; Calvo R; Rodríguez-Sasiaín JM; Jimenez R; Aguirre C; du Souich P
    Eur J Clin Pharmacol; 1995; 48(3-4):295-7. PubMed ID: 7589058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hydralazine on the elimination of antipyrine in the rat.
    Svensson CK; Knowlton PW; Ware JA
    Pharm Res; 1987 Dec; 4(6):515-8. PubMed ID: 3508566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prizidilol hydrochloride (SK & F 92657), a new antihypertensive agent with beta-adrenoceptor antagonist and vasodilator activity with propranolol and hydralazine in normal volunteers.
    Steiner JA; Clancy A; Manghani KK; James IM
    Br J Clin Pharmacol; 1981 Oct; 12(4):573-8. PubMed ID: 6117309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
    McLean AJ; Drummer OH; Smith HJ; Froomes P; McNeil JJ
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():147-51. PubMed ID: 2550637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative account of propranolol metabolism in urine of normal man.
    Walle T; Walle UK; Olanoff LS
    Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques.
    Bargar EM; Walle UK; Bai SA; Walle T
    Drug Metab Dispos; 1983; 11(3):266-72. PubMed ID: 6135586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.